JSW Cement IPO: Price band set at Rs 139-147; check key dates, issue details, and more
The anchor book will open a day prior, on Tuesday, August 6. Retail investors can bid for a minimum of 102 shares and in multiples thereof.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Data Science
MCA
Others
Operations Management
PGDM
CXO
Product Management
Technology
Project Management
healthcare
Cybersecurity
Digital Marketing
Data Analytics
others
Healthcare
Degree
Leadership
MBA
Design Thinking
Finance
Public Policy
Artificial Intelligence
Data Science
Management
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK DABS India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
E&ICT Academy, Indian Institute of Technology Guwahati
CERT-IITG Prof Cert in DS & BA with GenAI India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
E&ICT Academy, Indian Institute of Technology Guwahati
CERT-IITG Postgraduate Cert in AI and ML India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIT Madras
CERT-IITM Advanced Cert Prog in AI and ML India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
30 Weeks
IIM Kozhikode
SEPO - IIMK-AI for Senior Executives India
Starts on
undefined
Get Details
JSW Cement IPO Structure and Allocation
The IPO comprises a fresh issue of equity shares worth Rs 1,600 crore and an offer for sale (OFS) of shares aggregating to Rs 2,000 crore. The public issue has been structured with up to 50% reserved for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs), and at least 35% for retail investors.
Within the OFS, Apollo Management, through its affiliate AP Asia Opportunistic Holdings Pte Ltd, will sell shares worth Rs 931.80 crore, while Synergy Metals Investments Holding Ltd will offer shares valued at Rs 938.50 crore, and the
State Bank of India
(SBI) will divest shares totalling Rs 129.70 crore.
Live Events
Synergy Metals is a subsidiary of a private equity fund founded in 2015 by former ArcelorMittal executive Sudhir Maheshwari.
Also Read:
These 10 stocks delivered consistent dividend yields over the last 3 years
Use of Proceeds
According to the draft documents, JSW Cement plans to allocate Rs 800 crore to partly fund a new integrated cement facility in Nagaur, Rajasthan, and Rs 520 crore for the repayment or prepayment of its existing borrowings. The remaining funds will be designated for general corporate expenditures.
Mumbai-based JSW Cement had initially planned to raise Rs 4,000 crore—split equally between a fresh issue and an offer for sale (OFS). However, as per the latest Red Herring Prospectus (RHP), the size of the fresh issue has been reduced by Rs 400 crore.
JSW Cement IPO Key Dates
The basis of allotment is expected to be finalised on Tuesday, August 12. Refunds will be processed on Wednesday, August 13, and shares will be credited to demat accounts the same day. The stock is likely to debut on the BSE and NSE on Thursday, August 14.
Financial Performance
JSW Cement reported Rs 6,028 crore in revenue from operations in FY24, up from Rs 5,837 crore a year earlier. However, net profit fell to Rs 62 crore from Rs 104 crore in FY23.
JSW Cement IPO Lead Managers
JM Financial
,
Axis Capital
, Citigroup, and Kotak Investment Banking are the book-running lead managers for the IPO.
Company Details
JSW Cement, a part of the JSW Group, manufactures eco-friendly cement with a focus on sustainability and innovation in the construction sector.
The company operates seven plants across India, including one integrated unit, one clinker unit, and five grinding units. These facilities are located in Andhra Pradesh (Nandyal), Karnataka (Vijayanagar), Tamil Nadu (Salem), Maharashtra (Dolvi), West Bengal (Salboni), and Odisha (Jajpur), along with the majority-owned clinker unit of Shiva Cement in Odisha.
As of 31 March 2025, JSW Cement had a total installed grinding capacity of 20.60 million metric tonnes per annum (MMTPA), distributed across regions as follows: 11.00 MMTPA in the South, 4.50 MMTPA in the West, and 5.10 MMTPA in the East.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Gujarat remains top exporting state in FY25 with ₹9.83 trn exports: FIEO
Gujarat retained its position as India's top exporting state in 2024-25, with outbound shipments worth Rs 9.83 lakh crore, accounting for 26.6 per cent of the country's total exports, FIEO said on Tuesday. It said despite a marginal dip from the previous year, Gujarat's exports remained significantly ahead of all other states, nearly Rs 4.3 lakh crore more than Maharashtra (Rs 5,57,271 crore), the second-ranked state. Maharashtra is followed by Tamil Nadu, Karnataka, Uttar Pradesh, Andhra Pradesh and Telangana, according to the analysis of the Federation of Indian Export Organisations (FIEO). "In 2024-25, Gujarat reaffirmed its leadership as India's top exporting state, accounting for Rs 9.83 lakh crore, which is 26.6 per cent of the country's total exports," it said. It added that Gujarat's export dominance continues to be driven by a few high-performing districts, with Jamnagar maintaining a commanding lead at Rs 3.63 lakh crore, largely owing to its petroleum and refinery exports. Jamnagar contributes over one-third of the state's total. The top five export commodities from the state are Petroleum Products, Gems and Jewellery, Organic Chemicals, Pharmaceuticals, and Engineering Goods (Machinery). In 2024-25, Uttar Pradesh contributes Rs 1.86 lakh crore to India's total exports of Rs 37.02 lakh crore. This accounts for 5 per cent of the country's total exports, positioning Uttar Pradesh as an important player in India's export landscape. "Uttar Pradesh has demonstrated a commendable diversification in its export markets, reaching both traditional and emerging economies across continents," it said, adding that the US continues to be the top export destination of the state.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Assetz acquires 11.5 acres in Bengaluru for ₹1,400 crore housing project
Bengaluru-based real estate developer Assetz has acquired an 11.5-acre land parcel on Old Madras Road (OMR)–Hoskote Highway in East Bengaluru to develop a luxury residential community with an estimated gross development value (GDV) exceeding ₹1,400 crore. The strategic move is backed by Motilal Oswal Alternates (MOA). The company stated that the acquisition includes a joint development component with Vanshee Builders & Developers Pvt Ltd. The upscale residential project, featuring highway-facing support amenities, will span 1.4 million square feet of saleable built-up area (SBA) and comprise approximately 800 units. This move further strengthens Assetz's position in East Bengaluru — a market where it has already made a mark with projects such as Marq, Bloom & Dell, Sun & Sanctum, 66, and Shibui. 'Strategic land acquisition has always been fundamental to our development approach, laying the groundwork well before execution begins. In the past two years alone, we have secured a pipeline of 17 million square feet across 19 projects with the potential to deliver 9,000 homes. With 10 launches this year, we are committed to delivering homes that offer long-term value to our buyers and communities alike,' said Sunil Pareek, executive director, Assetz. In July, Motilal Oswal Alternates closed its sixth real estate fund with a corpus of ₹2,000 crore. Anand Lakhotia, managing director and co-head (real estate) at Motilal Oswal Alternates, commented, 'We are well-positioned to support quality land acquisitions. This association reflects our belief in Assetz's vision of a professional residential platform with established execution capabilities. Their emphasis on good governance, supported by a steady track record, is in line with our strategy of investing in top-performing developers.' Since 2006, Assetz has delivered 20 residential and commercial projects totalling approximately 15 million square feet. In the residential segment, the company has continued to scale, building a portfolio of 46 projects — delivered, launched, and under approval — with a cumulative development potential of 45 million square feet.
